Fair point Fidosnos, but are their patients all on gemcitabine? I thought they were on a number of chemo regimes, all with better OS figures than the ones they've chosen to reference. Plus, if their patients are on FOLFIRINOX, these small populations would likely result in 16 months and 15.4 months being considered (statistically) the same.
DYOR, but IMHO this ANN smells like its been worded to make the OS results sound more impressive than they actually are.
OSL Price at posting:
6.8¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)